Inventor
VAN PEL ALINE
BE19 patents
⚠️ This page may combine multiple inventors who share the name “VAN PEL ALINE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LUDWIG INST CANCER RES
18 patentsUS5342774AAug 30, 1994
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
LUDWIG INST CANCER RES232 citations98
US5620886AApr 15, 1997
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES75 citations96
US5487974AJan 30, 1996
Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
LUDWIG INST CANCER RES59 citations95
US6201111B1Mar 13, 2001
Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
LUDWIG INST CANCER RES15 citations92
US5925729AJul 20, 1999
Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
LUDWIG INST CANCER RES31 citations92
US5854203ADec 29, 1998
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES25 citations92
US5837476ANov 17, 1998
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
LUDWIG INST CANCER RES19 citations92
US5747271AMay 5, 1998
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES39 citations92
US5744316AApr 28, 1998
Isolated, tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES28 citations92
US5530096AJun 25, 1996
Isolated, tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES22 citations92
US5856091AJan 5, 1999
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES16 citations82
US6669946B2Dec 30, 2003
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES5 citations73
US7547439B1Jun 16, 2009
Tumor rejection antigens
LUDWIG INST CANCER RES5 citations71
US5843688ADec 1, 1998
Isolated tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES2 citations62
USRE40089EFeb 19, 2008
Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
LUDWIG INST CANCER RES0 citations52
US7923534B1Apr 12, 2011
Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3
LUDWIG INST CANCER RES0 citations51
US6284476B1Sep 4, 2001
Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES0 citations51
US7785881B2Aug 31, 2010
MAGE-C2 antigenic peptides and uses thereof
LUDWIG INST CANCER RES0 citations48